|
|
Anaptysbio inc
ANAB's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Anaptysbio Inc growth rates, revenue grew
by 804.67 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 462
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Anaptysbio Inc net loss decreased from $-37 millions, to $-33 millions in III. Quarter 2024,
• More on ANAB's Growth
|
|
Anaptysbio Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.41 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
• More on ANAB's Valuation
|
|
|
|
|
Anaptysbio Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.41 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
Anaptysbio Inc Price to Book Ratio is at 8.65 lower than Industry Avg. of 81.1. and higher than S&P 500 Avg. of 0.01
• More on ANAB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
